Cargando…

Isradipine plasma pharmacokinetics and exposure–response in early Parkinson’s disease

OBJECTIVES: Isradipine is a dihydropyridine calcium channel inhibitor that has demonstrated concentration‐dependent neuroprotective effects in animal models of Parkinson’s disease (PD) but failed to show efficacy in a phase 3 clinical trial. The objectives of this study were to model the plasma phar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Venuto, Charles S., Yang, Luoying, Javidnia, Monica, Oakes, David, James Surmeier, D., Simuni, Tanya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951102/ https://www.ncbi.nlm.nih.gov/pubmed/33460320 http://dx.doi.org/10.1002/acn3.51300

Ejemplares similares

A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY‐PD III)
por: Biglan, Kevin M., et al.
Publicado: (2017)

Nano-colloidal carrier via polymeric coating for oral delivery of isradipine
por: Kumar, Vikash, et al.
Publicado: (2017)

S53. COMPARISON OF RALOXIFENE AND ISRADIPINE AS AN ADJUNCTIVE TREATMENT IN COGNITIVE DEFICITS OF PATIENTS WITH SCHIZOPHRENIA
por: Vahdani, Bita, et al.
Publicado: (2018)

Development and evaluation of isradipine via rutin-loaded coated solid–lipid nanoparticles
por: Kumar, Vikash, et al.
Publicado: (2018)

Practical Radiosynthesis and Preclinical Neuroimaging of [(11)C]isradipine, a Calcium Channel Antagonist
por: Rotstein, Benjamin H., et al.
Publicado: (2015)

Novel Approach to Movement Disorder Society–Unified Parkinson's Disease Rating Scale Monitoring in Clinical Trials: Longitudinal Item Response Theory Models
por: Luo, Sheng, et al.
Publicado: (2021)

Predictive Value of Verbatim Parkinson’s Disease Patient-Reported Symptoms of Postural Instability and Falling
por: Javidnia, Monica, et al.
Publicado: (2021)

A translational continuum of model systems for evaluating treatment strategies in Alzheimer’s disease: isradipine as a candidate drug
por: Copenhaver, Philip F., et al.
Publicado: (2011)

Isradipine therapy in Cacna1d(Ile772Met/+) mice ameliorates primary aldosteronism and neurologic abnormalities
por: Stölting, Gabriel, et al.
Publicado: (2023)

Feasibility and Preliminary Efficacy of Isradipine During Outpatient Buprenorphine Stabilization and Detoxification: A Pilot Randomized, Placebo-Controlled Trial
por: Kumar, Nihit, et al.
Publicado: (2020)

Calcium, Bioenergetics, and Parkinson’s Disease
por: Zampese, Enrico, et al.
Publicado: (2020)

Tracking Emergence of New Motor and Non-Motor Symptoms Using the MDS-UPDRS: A Novel Outcome Measure for Early Parkinson’s Disease?
por: Tosin, Michelle H.S., et al.
Publicado: (2022)

A molecular approach to treating cognition in schizophrenia by calcium channel blockade: An open-label pilot study of the calcium-channel antagonist isradipine
por: Burdick, Katherine E., et al.
Publicado: (2020)

Predictors of time to initiation of symptomatic therapy in early Parkinson's disease
por: Simuni, Tanya, et al.
Publicado: (2016)

Striatal synaptic adaptations in Parkinson’s disease
por: Shen, Weixing, et al.
Publicado: (2022)

A New Era: The Growth of Video-Based Visits for Remote Management of Persons with Parkinson’s Disease
por: Larson, Danielle N., et al.
Publicado: (2021)

Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice
por: Wang, Qi-Min, et al.
Publicado: (2017)

Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial
por: Simuni, Tanya, et al.
Publicado: (2020)

CLINICAL TRIAL HIGHLIGHTS: 1. GENE THERAPY FOR PARKINSON’S, 2. PHASE 3 STUDY IN FOCUS - INTEC PHARMA’S ACCORDION PILL, 3. CLINICAL TRIALS RESOURCES
por: McFarthing, Kevin, et al.
Publicado: (2019)

Increasing Efficiency of Recruitment in Early Parkinson’s Disease Trials: A Case Study Examination of the STEADY-PD III Trial
por: Berk, Sarah, et al.
Publicado: (2017)

Pathway‐Specific Remodeling of Thalamostriatal Synapses in a Mouse Model of Parkinson's Disease
por: Tanimura, Asami, et al.
Publicado: (2022)

Identifying prodromal symptoms at high specificity for Parkinson’s disease
por: Jackson, Holly, et al.
Publicado: (2023)

Application of longitudinal item response theory models to modeling Parkinson’s disease progression
por: Zou, Haotian, et al.
Publicado: (2022)

Proposal for a Biologic Staging System of Parkinson’s Disease
por: Chahine, Lana M., et al.
Publicado: (2023)

Delayed Spine Pruning of Direct Pathway Spiny Projection Neurons in a Mouse Model of Parkinson’s Disease
por: Graves, Steven M., et al.
Publicado: (2019)

Prevalence and Incidence of Nonmotor Symptoms in Individuals with and Without Parkinson's Disease
por: Paracha, Mariam, et al.
Publicado: (2022)

Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

Rethinking the network determinants of motor disability in Parkinson’s disease
por: Surmeier, Dalton James, et al.
Publicado: (2023)

Effects of acute levodopa challenge on resting cerebral blood flow in Parkinson’s Disease patients assessed using pseudo-continuous arterial spin labeling
por: Chen, Yufen, et al.
Publicado: (2015)

Parkinson's disease: Is it a consequence of human brain evolution?
por: Diederich, Nico J., et al.
Publicado: (2019)

Parkinson’s Disease Subtypes: Critical Appraisal and Recommendations
por: Mestre, Tiago A., et al.
Publicado: (2021)

Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
por: Henrich, Martin T., et al.
Publicado: (2023)

Evaluation of an Interdisciplinary Screening Program for People With Parkinson Disease and Movement Disorders
por: Khan, Uzma, et al.
Publicado: (2020)

Deep Learning for Daily Monitoring of Parkinson’s Disease Outside the Clinic Using Wearable Sensors
por: Atri, Roozbeh, et al.
Publicado: (2022)

A Digital Architecture for the Real-Time Tracking of Wearing off Phenomenon in Parkinson’s Disease
por: Mezzina, Giovanni, et al.
Publicado: (2022)

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
por: Irwin, David J., et al.
Publicado: (2020)

Relative Meaningfulness and Impacts of Symptoms in People with Early-Stage Parkinson’s Disease
por: Mammen, Jennifer R., et al.
Publicado: (2023)

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

Population Pharmacokinetics and Exposure-Response Relationships of Naldemedine
por: Kubota, Ryuji, et al.
Publicado: (2018)

Liraglutide pharmacokinetics and exposure‐response in adolescents with obesity
por: Carlsson Petri, Kristin C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_20gcfctjt44208ookbom04jirk